{"title":"Real-World Use of Teprotumumab and Tocilizumab in Moderate-to-Severe Steroid-Resistant Thyroid Eye Disease","authors":"Anupam Kotwal","doi":"10.1089/ct.2023;35.364-367","DOIUrl":null,"url":null,"abstract":"Clinical Thyroidology®Vol. 35, No. 9 Thyroid Eye DiseaseReal-World Use of Teprotumumab and Tocilizumab in Moderate-to-Severe Steroid-Resistant Thyroid Eye DiseaseAnupam KotwalAnupam KotwalDivision of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, U.S.A.Search for more papers by this authorPublished Online:13 Sep 2023https://doi.org/10.1089/ct.2023;35.364-367AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 35Issue 9Sep 2023 Information© Copyright 2023, Mary Ann Liebert, Inc.To cite this article:Anupam Kotwal.Real-World Use of Teprotumumab and Tocilizumab in Moderate-to-Severe Steroid-Resistant Thyroid Eye Disease.Clinical Thyroidology®.Sep 2023.364-367.http://doi.org/10.1089/ct.2023;35.364-367Published in Volume: 35 Issue 9: September 13, 2023PDF download","PeriodicalId":72629,"journal":{"name":"Clinical thyroidology","volume":"30 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical thyroidology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/ct.2023;35.364-367","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Teprotumumab和Tocilizumab在中重度类固醇抵抗性甲状腺眼病中的实际应用
临床Thyroidology®卷。Teprotumumab和Tocilizumab在中重度类固醇抵抗性甲状腺眼病中的应用，内布拉斯加州大学医学中心内科糖尿病、内分泌和代谢科，奥巴马，内布拉斯加州。美国搜索本文作者的更多论文出版在线:2023年9月13日https://doi.org/10.1089/ct.2023;35.364-367AboutSectionsView文章查看全文pdf /EPUB下载CitationsTrack CitationsAdd to favorites返回出版物ShareShare onFacebookTwitterLinked InRedditEmail查看文章figuresreferencesrelateddetails卷35Issue 9Sep 2023信息©版权所有2023,Mary Ann Liebert，公司引用本文:Anupam Kotwal。Teprotumumab和Tocilizumab在中重度类固醇抵抗性甲状腺眼病中的实际应用临床Thyroidology®。Sep 2023.364-367.http://doi.org/10.1089/ct.2023;35.364-367Published Volume: 35 Issue: 2023年9月13日pdf下载
本文章由计算机程序翻译，如有差异，请以英文原文为准。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
